MCID: ESN004
MIFTS: 44

Eosinophilic Gastritis

Categories: Gastrointestinal diseases

Aliases & Classifications for Eosinophilic Gastritis

MalaCards integrated aliases for Eosinophilic Gastritis:

Name: Eosinophilic Gastritis 12 15 73
Eosinophilic Enteropathy 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:4030
ICD9CM 35 535.7
MeSH 44 C535952
NCIt 50 C27052
SNOMED-CT 68 196738004 66329006

Summaries for Eosinophilic Gastritis

MalaCards based summary : Eosinophilic Gastritis, also known as eosinophilic enteropathy, is related to gastroenteritis and esophagitis. An important gene associated with Eosinophilic Gastritis is IL5 (Interleukin 5), and among its related pathways/superpathways are ERK Signaling and PEDF Induced Signaling. The drugs Fluticasone and Budesonide have been mentioned in the context of this disorder. Affiliated tissues include testes, and related phenotypes are digestive/alimentary and hematopoietic system

Related Diseases for Eosinophilic Gastritis

Diseases related to Eosinophilic Gastritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 166)
# Related Disease Score Top Affiliating Genes
1 gastroenteritis 30.5 CCL11 IL4 IL5
2 esophagitis 29.9 CCL11 CCL26 IL13 IL5
3 hypereosinophilic syndrome 28.8 CCL11 IL13 IL3 IL4 IL5
4 eosinophilic enteropathy 11.2
5 pemphigoid gestationis 10.9 CCL11 IL5
6 chronic meningitis 10.9 CCL11 IL5
7 cytokine deficiency 10.8 IL13 IL5
8 angioimmunoblastic lymphadenopathy with dysproteinemia 10.8 IL13 IL5
9 fungal esophagitis 10.8 ATP12A ATP4A
10 bladder calculus 10.8 ATP12A ATP4A
11 gastrointestinal neuroendocrine benign tumor 10.8 ATP12A ATP4A
12 neonatal candidiasis 10.8 ATP12A ATP4A
13 respiratory syncytial virus infectious disease 10.8 IL13 IL5
14 photoallergic dermatitis 10.8 ATP12A ATP4A
15 squamous papillomatosis 10.8 ATP12A ATP4A
16 acute laryngitis 10.8 ATP12A ATP4A
17 gastroduodenal crohn's disease 10.8 ATP12A ATP4A
18 gastric neuroendocrine neoplasm 10.8 ATP12A ATP4A
19 toxic megacolon 10.8 ATP12A ATP4A
20 aspiration pneumonitis 10.8 ATP12A ATP4A
21 postsurgical hypothyroidism 10.8 ATP12A ATP4A
22 gastric antral vascular ectasia 10.8 ATP12A ATP4A
23 esophageal candidiasis 10.8 ATP12A ATP4A
24 duodenitis 10.8 ATP12A ATP4A
25 rumination disorder 10.8 ATP12A ATP4A
26 bile reflux 10.8 ATP12A ATP4A
27 granulomatous gastritis 10.8 ATP12A ATP4A
28 active peptic ulcer disease 10.8 ATP12A ATP4A
29 laryngeal disease 10.8 ATP12A ATP4A
30 ischemic neuropathy 10.8 ATP12A ATP4A
31 capillary disease 10.7 ATP12A ATP4A
32 chronic eosinophilic pneumonia 10.7 CCL11 IL5
33 cough variant asthma 10.7 IL4 IL5
34 peptic esophagitis 10.7 ATP12A ATP4A
35 paragonimiasis 10.7 IL13 IL5
36 duodenal disease 10.7 ATP12A ATP4A
37 dyskinesia of esophagus 10.7 ATP12A ATP4A
38 blepharoconjunctivitis 10.7 CCL11 IL4
39 egg allergy 10.7 IL4 IL5
40 hernia, hiatus 10.7 ATP12A ATP4A
41 congenital disorder of deglycosylation 10.7 ATP12A ATP4A
42 anismus 10.7 ATP12A ATP4A
43 esophageal atresia/tracheoesophageal fistula 10.7 ATP12A ATP4A
44 ascaris lumbricoides infection 10.7 IL13 IL5
45 scleritis 10.7 IL4 IL5
46 laryngitis 10.7 ATP12A ATP4A
47 papillary conjunctivitis 10.7 CCL11 IL4
48 laryngeal tuberculosis 10.7 ATP12A ATP4A
49 lymphocytic colitis 10.7 ATP12A ATP4A
50 trichinosis 10.7 IL4 IL5

Graphical network of the top 20 diseases related to Eosinophilic Gastritis:



Diseases related to Eosinophilic Gastritis

Symptoms & Phenotypes for Eosinophilic Gastritis

MGI Mouse Phenotypes related to Eosinophilic Gastritis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.86 IL18 IL33 IL4 ATP12A ATP4A IL5
2 hematopoietic system MP:0005397 9.85 IL13 IL15 IL18 IL33 IL4 ATP4A
3 immune system MP:0005387 9.65 IL13 IL15 IL18 IL33 IL4 ATP4A
4 respiratory system MP:0005388 9.17 IL13 IL33 IL4 IL5 CCL11 CCL24

Drugs & Therapeutics for Eosinophilic Gastritis

Drugs for Eosinophilic Gastritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 107)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluticasone Approved, Experimental, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 90566-53-3 62924
2
Budesonide Approved Phase 4,Phase 3,Phase 2,Not Applicable 51333-22-3 63006 5281004
3
Dexlansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 138530-94-6, 103577-45-3 9578005
4
Lansoprazole Approved, Investigational Phase 4,Phase 2,Phase 1,Not Applicable 103577-45-3 3883
5
Menthol Approved Phase 4 2216-51-5 16666
6 Anti-Asthmatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Respiratory System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Anti-Allergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
11 Bronchodilator Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Dermatologic Agents Phase 4,Phase 3,Phase 2,Not Applicable
13 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
14 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Cromolyn Sodium Phase 4
19 Antacids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
20 Anti-Ulcer Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
21 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
22 Proton Pump Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1,Not Applicable
23 Soy Bean Nutraceutical Phase 4,Phase 2,Phase 3,Not Applicable
24 Olive Nutraceutical Phase 4
25
Montelukast Approved Phase 3,Phase 1,Not Applicable 158966-92-8 5281040
26
Esomeprazole Approved, Investigational Phase 2, Phase 3,Not Applicable 161796-78-7, 119141-88-7 4594 9579578
27 Leukotriene Antagonists Phase 3,Phase 1,Not Applicable
28
Omalizumab Approved, Investigational Phase 2,Phase 1 242138-07-4
29
Infliximab Approved Phase 2 170277-31-3
30
Angiotensin II Approved, Investigational Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
31
Losartan Approved Phase 2 114798-26-4 3961
32
Bethanechol Approved Phase 2 674-38-4 2370
33 Indoleacetic Acids Phase 2
34 Antibodies Phase 2,Phase 1
35 Antibodies, Monoclonal Phase 2,Phase 1
36 Immunoglobulins Phase 2,Phase 1
37 Antirheumatic Agents Phase 2
38 interferons Phase 1, Phase 2
39 Neurotransmitter Agents Phase 2,Not Applicable
40 Pharmaceutical Solutions Phase 2,Not Applicable
41 Angiotensin II Type 1 Receptor Blockers Phase 2
42 Angiotensin Receptor Antagonists Phase 2
43 Angiotensinogen Phase 2
44 Anti-Arrhythmia Agents Phase 2
45 Antihypertensive Agents Phase 2
46 Vasoconstrictor Agents Phase 2
47 mometasone furoate Phase 2
48 Cholinergic Agents Phase 2
49
Lactulose Approved Phase 1 4618-18-2 11333
50
Mannitol Approved, Investigational Phase 1 69-65-8 453 6251

Interventional clinical trials:

(show top 50) (show all 125)
# Name Status NCT ID Phase Drugs
1 Oral Cromolyn Sodium for the Treatment of Eosinophilic Esophagitis Completed NCT02371941 Phase 4 oral cromolyn sodium;Placebo
2 Dietetic Versus Topical Steroids for Pediatric Eosinophilic Esophagitis Completed NCT01846962 Phase 4 Budesonide;Fluticasone;Oral Viscous Budesonide (OVB)
3 Budesonide Versus Fluticasone for Treatment of Eosinophilic Esophagitis Active, not recruiting NCT02019758 Phase 4 Oral Viscous Budesonide;Fluticasone MDI;Placebo slurry;Placebo inhaler
4 The Frequency of Eosinophilic Esophagitis in Patients With Heartburn That is Refractory to Proton Pump Inhibitors Terminated NCT01404832 Phase 4 Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms
5 Eosinophilic Esophagitis Treatment: Montelukast vs Fluticasone Unknown status NCT01702701 Phase 3 Montelukast;Fluticasone
6 Eosinophilic Esophagitis (EoE) Intervention Trial-Randomized 1 Food Elimination vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids Unknown status NCT02610816 Phase 2, Phase 3 Flovent (fluticasone propionate)
7 Open-Label Extension Study of Reslizumab in Pediatric Subjects With Eosinophilic Esophagitis Completed NCT00635089 Phase 3 reslizumab
8 Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis Completed NCT02434029 Phase 3 Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
9 Efficacy and Safety Study of Reslizumab to Treat Eosinophilic Esophagitis in Subjects Aged 5 to 18 Years Completed NCT00538434 Phase 2, Phase 3
10 A Study Comparing Swallowed Flovent and Placebo in Patients With Eosinophilic Disorders Completed NCT00266578 Phase 3 Fluticasone Propionate
11 The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis Completed NCT00728481 Phase 2, Phase 3 Esomeprazole;Budesonide
12 Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis Recruiting NCT02493335 Phase 3 Budesonide 0.5mg orodispersible tablet twice daily;Budesonide 1mg orodispersible tablet twice daily;Placebo orodispersible tablet twice daily
13 Continuation Study With Budesonide Oral Suspension (BOS) for Adolescent and Adult Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03245840 Phase 3 Budesonide oral suspension
14 A Placebo- Controlled Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved Recruiting NCT02605837 Phase 3 OBS;Placebo
15 An Extension Study to Evaluate Maintenance of Efficacy and Long-term Treatment Effect of Oral Budesonide Suspension (OBS) in Adults and Adolescents With Eosinophilic Esophagitis (EoE) Recruiting NCT02736409 Phase 3 Oral Budesonide Suspension (OBS);Placebo
16 SOFEED: Six Food vs. One Food Eosinophilic Esophagitis Diet Study Recruiting NCT02778867 Phase 2, Phase 3 Flovent
17 Safety and Efficacy of Three Doses of Oral Fluticasone Propionate in Adults With Eosinophilic Esophagitis Not yet recruiting NCT02873468 Phase 2, Phase 3 EMS Fluticasone 1;EMS Fluticasone 2;EMS Fluticasone 3
18 Dose-Ranging Study of Oral Viscous Budesonide in Pediatrics With Eosinophilic Esophagitis Completed NCT00762073 Phase 2 budesonide;placebo
19 A Study of Flovent in Patients With Eosinophilic Esophagitis Completed NCT00426283 Phase 2 Flovent
20 Budesonide for Eosinophilic Esophagitis Completed NCT00271349 Phase 2 Budesonide
21 Topical Steroid Treatment for Eosinophilic Esophagitis Completed NCT00275561 Phase 2 Fluticasone;Placebo
22 Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension vs. Placebo in Eosinophilic Esophagitis Completed NCT02280616 Phase 2 low dose budesonide tablet;high dose budesonide tablet;high dose budesonide suspension;Placebo
23 Dose Ranging Study of RPC4046 in Eosinophilic Esophagitis Completed NCT02098473 Phase 2 RPC4046;Placebo
24 Proof of Concept Study of OC000459 in Eosinophilic Esophagitis Completed NCT01056783 Phase 2 OC000459;Placebo
25 Use of Topical Budesonide in the Treatment of Eosinophilic Esophagitis Completed NCT00638456 Phase 2 Budesonide plus Prevacid;placebo plus Prevacid
26 Safety and Tolerability Study of Oral EUR-1100 to Treat Eosinophilic Esophagitis Completed NCT01386112 Phase 1, Phase 2 EUR-1100;placebo
27 Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis Completed NCT01022970 Phase 2 QAX576 placebo;QAX576
28 Study of Dupilumab in Adult Patients With Active Eosinophilic Esophagitis (EoE) Completed NCT02379052 Phase 2 Dupilumab;Placebo
29 A Pilot Study of the Treatment of Eosinophilic Esophagitis With Omalizumab Completed NCT00123630 Phase 2 omalizumab;Placebo
30 Comparison of Esomeprazole to Aerosolized, Swallowed Fluticasone for Eosinophilic Esophagitis Completed NCT00123656 Phase 2 esomeprazole;fluticasone
31 OBS in Adolescent and Adults With EOE: A Phase II, Randomized, Double-Blind, Placebo Controlled, Study With an Open Label Extension Completed NCT01642212 Phase 2 Oral Budesonide Suspension (MB-9);Placebo
32 Off Label Use of Infliximab in Adult Patients With Severe Eosinophilic Esophagitis Completed NCT00523354 Phase 2 Infliximab
33 Intravenous Mepolizumab In Children With Eosinophilic Esophagitis Completed NCT00358449 Phase 2 mepolizumab
34 Omalizumab to Treat Eosinophilic Gastroenteritis Completed NCT00084097 Phase 2 Omalizumab
35 An Evaluation Of Mepolizumab In Therapy Of Eosinophilic Oesophagitis In Adult Patients Completed NCT00274703 Phase 2 mepolizumab
36 Anti-Interleukin-5 Antibody to Treat Hypereosinophilic Syndrome Completed NCT00017862 Phase 2 SCH55700
37 Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome Completed NCT00266565 Phase 1, Phase 2 Mepolizumab
38 Benralizumab for Eosinophilic Gastritis Recruiting NCT03473977 Phase 1, Phase 2
39 A Study of AK002 in Patients With Eosinophilic Gastritis With or Without Eosinophilic Gastroenteritis Recruiting NCT03496571 Phase 2 AK002
40 Eosinophilic Esophagitis Clinical Therapy Comparison Trial Recruiting NCT01821898 Phase 2 Oral Budesonide
41 Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) Recruiting NCT03191864 Phase 2 APT-1011;Placebo
42 An Open-Label Trial of Losartan Potassium in Participants With Eosinophilic Esophagitis (EoE) Recruiting NCT03029091 Phase 2 Losartan Potassium
43 Milk Patch for Eosinophilic Esophagitis Active, not recruiting NCT02579876 Phase 2 Viaskin Milk 500 mcg;Viaskin Placebo
44 Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD Active, not recruiting NCT01808196 Phase 2 Losartan Potassium
45 Mometasone-furoate for Treatment of Eosinophilic Esophagitis - a Randomized Placebo Controlled Study. Enrolling by invitation NCT02113267 Phase 2 Mometasone furoate;Placebo
46 Bethanechol for Eosinophilic Esophagitis Terminated NCT02058537 Phase 2 Bethanechol
47 Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis Withdrawn NCT01479231 Phase 1, Phase 2 dexlansoprazole
48 Evaluation of the Safety and Effectiveness of Tailored Transoral Incisionless Fundoplication (TIF) Using EsophyX for the Treatment of GERD Withdrawn NCT01025739 Phase 2
49 Intestinal Permeability in Response to Treatment in Eosinophilic Esophagitis Patients Completed NCT01641913 Phase 1
50 Identifying Responders to Xolair (Omalizumab) Using Eosinophilic Esophagitis as a Disease Model Completed NCT01040598 Phase 1

Search NIH Clinical Center for Eosinophilic Gastritis

Cochrane evidence based reviews: eosinophilic enteropathy

Genetic Tests for Eosinophilic Gastritis

Anatomical Context for Eosinophilic Gastritis

MalaCards organs/tissues related to Eosinophilic Gastritis:

41
Testes

Publications for Eosinophilic Gastritis

Articles related to Eosinophilic Gastritis:

(show all 42)
# Title Authors Year
1
Impact on Health-Related Quality of Life in Adults with Eosinophilic Gastritis and Gastroenteritis: A Qualitative Assessment. ( 29476289 )
2018
2
Eosinophilic gastritis with involvement of esophageal gastricA inlet patch. ( 29108982 )
2017
3
Gene Expression Patterns in Distinct Endoscopic Findings for Eosinophilic Gastritis in Children. ( 28526277 )
2017
4
Hypereosinophilic Syndrome With Eosinophilic Gastritis. ( 28491930 )
2017
5
Primary Eosinophilic Gastritis in a Child with Gastric Outlet Obstruction. ( 26768007 )
2016
6
Prevalence of Eosinophilic Gastritis, Gastroenteritis, and Colitis: Estimates From a National Administrative Database. ( 25988554 )
2015
7
Eosinophilic Gastritis Presenting as Tissue Necrosis. ( 26668805 )
2015
8
A man with unsuspected marine eosinophilic gastritis. ( 25467651 )
2015
9
Histologic eosinophilic gastritis is a systemic disorder associated with blood and extragastric eosinophilia, TH2A immunity, and a unique gastric transcriptome. ( 25234644 )
2014
10
Eosinophilic gastritis in children: clinicopathological correlation, disease course, and response to therapy. ( 24957155 )
2014
11
Eosinophilic gastritis with gastric outlet obstruction mimicking infantile hypertrophic pyloric stenosis. ( 25222812 )
2014
12
Rare association of IgA nephropathy with nephrotic syndrome in a patient with eosinophilic gastritis. ( 24969211 )
2014
13
A Childhood Case of Eosinophilic Gastritis and Protein-Losing Enteropathy. ( 24351503 )
2013
14
Gastric pneumatosis with associated eosinophilic gastritis in four black and white ruffed lemurs (Varecia variegata variegata). ( 23505706 )
2013
15
Snakeskin-like pattern mimicking portal hypertensive gastropathy in patient with eosinophilic gastritis. ( 22211417 )
2012
16
Eosinophilic gastritis: histopathological characterization and quantification of the normal gastric eosinophil content. ( 21169993 )
2011
17
Transmural eosinophilic gastritis with gastric outlet obstruction: case report and review of the literature. ( 20501003 )
2010
18
A case of eosinophilic gastritis secondary to ulcerative colitis. ( 20533119 )
2010
19
Eosinophilic gastritis masquerading as gastric carcinoma. ( 20551571 )
2010
20
Eosinophilic gastritis with idiopathic thrombocytopaenic purpura: coincidence or association? ( 19741546 )
2009
21
Collagenous colitis and eosinophilic gastritis in a 4-year old girl: a case report and review of the literature. ( 17718794 )
2007
22
Eosinophilic gastritis; an unusual and overlooked cause of chronic abdominal pain. ( 18693615 )
2007
23
Symptomatic eosinophilic gastritis cured with Helicobacter pylori eradication. ( 16284301 )
2005
24
Eosinophilic gastritis--an unusual cause of gastric outlet obstruction. ( 11400803 )
2001
25
Eosinophilic gastritis due to Anisakis: a case report. ( 10757855 )
2000
26
Cancer-like eosinophilic gastritis. ( 7956968 )
1994
27
Corticosteroid resistance in eosinophilic gastritis--relation to in vitro eosinophil survival and interleukin 5. ( 8452321 )
1993
28
Failure of ranitidine and omeprazole treatment in eosinophilic gastritis with ulceration. ( 1763563 )
1991
29
Superficial eosinophilic gastritis in laboratory beagle dogs attributable probably to diet. ( 2385038 )
1990
30
General diagnosis case of the day. Eosinophilic gastritis. ( 2718869 )
1989
31
Eosinophilic gastritis. ( 3102801 )
1987
32
Diffuse eosinophilic gastritis. ( 7097139 )
1982
33
Case report: eosinophilic gastritis simulating a neoplasm. ( 736058 )
1978
34
Scirrhous eosinophilic gastritis in dogs with gastric arteritis. ( 919234 )
1977
35
Eosinophilic gastritis. Radiologic-pathologic correlation (RPC) from the Armed Forces Institute of Pathology (AFIP). ( 935469 )
1976
36
Endoscopic diagnosis of eosinophilic gastritis. ( 4648828 )
1972
37
Eosinophilic gastritis. A case report. ( 4329046 )
1971
38
Eosinophilic gastritis: a case report and etiological investigation. ( 4099423 )
1971
39
Polypoid eosinophilic gastritis. ( 5435951 )
1970
40
Eosinophilic gastritis. ( 6071536 )
1967
41
Primary infiltrative eosinophilic gastritis, enteritis and peritonitis; clinical and pathological manifestations of hypersensitivity. ( 14366111 )
1955
42
A case of eosinophilic gastritis. ( 14895945 )
1951

Variations for Eosinophilic Gastritis

Expression for Eosinophilic Gastritis

Search GEO for disease gene expression data for Eosinophilic Gastritis.

Pathways for Eosinophilic Gastritis

Pathways related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

(show all 29)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.71 CCL11 CCL24 CCL26 IL13 IL15 IL18
2
Show member pathways
13.53 CCL11 CCL24 CCL26 IL13 IL15 IL18
3
Show member pathways
13.35 CCL11 CCL24 CCL26 IL13 IL15 IL18
4
Show member pathways
13.25 CCL11 IL13 IL15 IL18 IL3 IL33
5
Show member pathways
13.23 CCL11 CCL24 CCL26 IL13 IL15 IL18
6
Show member pathways
13.12 CCL11 CCL24 CCL26 IL13 IL15 IL18
7 12.74 IL13 IL15 IL3 IL4 IL5
8
Show member pathways
12.71 CCL11 FOXP3 IL13 IL15 IL18 IL3
9
Show member pathways
12.69 IL13 IL15 IL18 IL33 IL4
10
Show member pathways
12.55 IL13 IL15 IL18 IL3 IL4 IL5
11
Show member pathways
12.47 IL13 IL3 IL4 IL5
12
Show member pathways
12.38 FOXP3 IL13 IL18 IL4 IL5
13
Show member pathways
12.24 CCL11 IL13 IL4 IL5
14 11.94 IL15 IL3 IL4 IL5
15 11.93 CCL11 IL13 IL18 IL4
16
Show member pathways
11.88 CCL11 CCL24 CCL26
17 11.79 IL3 IL4 IL5
18
Show member pathways
11.73 FOXP3 IL3 IL4 IL5
19 11.71 IL13 IL4 IL5
20 11.64 IL13 IL15 IL18 IL33 IL4 IL5
21 11.62 CCL11 CCL26 IL4 IL5
22
Show member pathways
11.62 CCL11 CCL24 CCL26 IL13 IL15 IL18
23 11.61 CCL11 IL13 IL4 IL5
24 11.46 IL13 IL18 IL4
25 11.3 CCL11 FOXP3 IL13 IL33 IL4 IL5
26 11.2 IL13 IL15 IL3 IL4 IL5
27 11.17 IL13 IL4 IL5
28 11.09 IL13 IL18
29 10.61 IL13 IL15 IL18 IL33 IL4 IL5

GO Terms for Eosinophilic Gastritis

Cellular components related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CCL11 CCL24 CCL26 IL13 IL15 IL18
2 extracellular space GO:0005615 9.36 ATP4A CCL11 CCL24 CCL26 IL13 IL15

Biological processes related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.85 CCL24 CCL26 IL15 IL18 IL3
2 cytokine-mediated signaling pathway GO:0019221 9.85 CCL11 IL13 IL18 IL3 IL4 IL5
3 chemotaxis GO:0006935 9.83 CCL11 CCL24 CCL26
4 cellular response to tumor necrosis factor GO:0071356 9.82 CCL11 CCL24 CCL26
5 inflammatory response GO:0006954 9.8 CCL11 CCL24 CCL26 IL13 IL15 IL18
6 cellular response to interferon-gamma GO:0071346 9.78 CCL11 CCL24 CCL26
7 cellular response to interleukin-1 GO:0071347 9.77 CCL11 CCL24 CCL26
8 chemokine-mediated signaling pathway GO:0070098 9.76 CCL11 CCL24 CCL26
9 positive regulation of endothelial cell proliferation GO:0001938 9.75 CCL11 CCL24 CCL26
10 neutrophil chemotaxis GO:0030593 9.73 CCL11 CCL24 CCL26
11 positive regulation of actin filament polymerization GO:0030838 9.71 CCL11 CCL24 CCL26
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.71 IL13 IL15 IL18 IL3
13 monocyte chemotaxis GO:0002548 9.7 CCL11 CCL24 CCL26
14 positive regulation of B cell proliferation GO:0030890 9.69 IL13 IL4 IL5
15 ATP hydrolysis coupled proton transport GO:0015991 9.66 ATP12A ATP4A
16 negative regulation of interferon-gamma production GO:0032689 9.66 FOXP3 IL33
17 positive regulation of interleukin-4 production GO:0032753 9.65 FOXP3 IL33
18 cellular sodium ion homeostasis GO:0006883 9.65 ATP12A ATP4A
19 lymphocyte chemotaxis GO:0048247 9.65 CCL11 CCL24 CCL26
20 positive regulation of macrophage activation GO:0043032 9.64 IL13 IL33
21 cellular potassium ion homeostasis GO:0030007 9.63 ATP12A ATP4A
22 sodium ion export across plasma membrane GO:0036376 9.63 ATP12A ATP4A
23 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.62 ATP12A ATP4A
24 positive regulation of interleukin-17 production GO:0032740 9.62 IL15 IL18
25 positive regulation of immunoglobulin secretion GO:0051024 9.61 IL33 IL5
26 eosinophil chemotaxis GO:0048245 9.61 CCL11 CCL24 CCL26
27 immune response GO:0006955 9.61 CCL11 CCL24 CCL26 IL13 IL15 IL18
28 positive regulation of interleukin-13 production GO:0032736 9.6 IL33 IL4
29 positive regulation of natural killer cell proliferation GO:0032819 9.57 IL15 IL18
30 positive regulation of tissue remodeling GO:0034105 9.55 IL15 IL18
31 positive regulation of inflammatory response GO:0050729 9.55 CCL24 CCL26 IL15 IL18 IL33
32 type 2 immune response GO:0042092 9.5 IL18 IL33 IL4
33 negative regulation of complement-dependent cytotoxicity GO:1903660 9.49 IL13 IL4
34 regulation of signaling receptor activity GO:0010469 9.32 CCL11 CCL24 CCL26 IL13 IL15 IL18

Molecular functions related to Eosinophilic Gastritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.63 IL3 IL4 IL5
2 chemokine activity GO:0008009 9.58 CCL11 CCL24 CCL26
3 receptor ligand activity GO:0048018 9.5 CCL11 CCL24 CCL26
4 sodium:potassium-exchanging ATPase activity GO:0005391 9.43 ATP12A ATP4A
5 CCR chemokine receptor binding GO:0048020 9.43 CCL11 CCL24 CCL26
6 potassium:proton exchanging ATPase activity GO:0008900 9.37 ATP12A ATP4A
7 cytokine receptor binding GO:0005126 9.33 IL13 IL15 IL4
8 cytokine activity GO:0005125 9.32 CCL11 CCL24 CCL26 IL13 IL15 IL18
9 CCR3 chemokine receptor binding GO:0031728 9.13 CCL11 CCL24 CCL26

Sources for Eosinophilic Gastritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....